TRPV6 and prostate carcinoma: The ability of 1,25-dihydroxyvitamin D3 to inhibit prostate growth has been demonstrated in primary cultured cells from normal tissues, benign prostatic hyperplasia (BPH) and prostate cancer, and several xenograft models of prostate cancer [5], however, no relation to TRPV6 responsiveness has been demonstrated so far.